Abstract
The recent outbreak of a novel coronavirus SARS-CoV-2 (also known as 2019-nCoV) threatens global health, given serious cause for concern. SARS-CoV-2 is a human-to-human pathogen that caused fever, severe respiratory disease and pneumonia (known as COVID-19). By press time, more than 70,000 infected people had been confirmed worldwide. SARS-CoV-2 is very similar to the severe acute respiratory syndrome (SARS) coronavirus broke out 17 years ago. However, it has increased transmissibility as compared with the SARS-CoV, e.g. very often infected individuals without any symptoms could still transfer the virus to others. It is thus urgent to develop a rapid, accurate and onsite diagnosis methods in order to effectively identify these early infects, treat them on time and control the disease spreading. Here we developed an isothermal LAMP based method-iLACO (isothermal LAMP based method for COVID-19) to amplify a fragment of the ORF1ab gene using 6 primers. We assured the species-specificity of iLACO by comparing the sequences of 11 related viruses by BLAST (including 7 similar coronaviruses, 2 influenza viruses and 2 normal coronaviruses). The sensitivity is comparable to Taqman based qPCR detection method, detecting synthesized RNA equivalent to 10 copies of 2019-nCoV virus. Reaction time varied from 15-40 minutes, depending on the loading of virus in the collected samples. The accuracy, simplicity and versatility of the new developed method suggests that iLACO assays can be conveniently applied with for 2019-nCoV threat control, even in those cases where specialized molecular biology equipment is not available.
Competing Interest Statement
Xiushan Yin and Wei-Hua Chen are co-founders for Biotech & Biomedicine Science (Shenyang) Co. Ltd and Pluri Biotech Co.Ltd. Xiushan Yin is the co-founder for Nanog Biotech Co.Ltd.
Funding Statement
This work was funded by 2020 LiaoNing Provence Key Research Project (1580441949000), Ganzhou COVID-19 Emergency Research Project.VP is funded by the Swedish Research Council (VR 2016-01842), a Wallenberg Academy Fellowship (KAW 2016.0123), the Swedish Foundations’ Starting Grant (Ragnar Söderberg Foundation), Karolinska Institutet (SciLifeLab Fellowship, SFO and KI funds) and a Joint China-Sweden mobility grant from STINT (CH2018-7750).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
COVID-19 samples were obtained from patients sent to the Shenyang Center for Disease Control And Prevention, and the nucleotide sequences were downloaded from NCBI (https://www.ncbi.nlm.nih.gov/) database.
